WORLD LARGEST HEALTHCARE COMPANY, JOHNSON AND JOHNSON SALES DROPPED BY NEARLY 1.4%
Johnson and Johnson reported sales of $20.24 billion in the first half of 2020. The company has reported a decrease in sales by 1.4% compared to H1 of 2019.
The company has reported a decrease in sales by nearly 11% in the second quarter of 2020. In the second quarter, the pharmaceutical segment of the company had an increase in sales by 2.1%.
Also read: The US FDA approved Janssen’s psoriasis blockbuster for Psoriatic Arthritis
The sales were primarily driven by Stelara (ustekinumab), Darzalex (daratumumab), Imbruvica (ibrutinib), Erleada (apalutamide), Tremfya (guselkumab), and Uptravi (selexipag). Biosimilars of Remicade (infliximab), and generics of Velcade (bortezomib), Zytiga (abiraterone acetate) hurt the sales.
The other segments of the company, however, were severely affected by the coronavirus. Consumer health sales dropped by 7%, and medical devices sales dropped by 34% in the second quarter of this year.
In the full-year guidance, the company is expecting a drop of 1% in operational sales compared to the last year.
Also read: JANSSEN STOPPED PHASE 3 TRIAL OF ITS BLOCKBUSTER
ROCHE SALES DROPPED BY 1%
Roche has reported $31.78 bn sales in the first half of 2020. The company has reported a 7% growth in sales in the first quarter, however, a 4% decline in the second quarter. The company witnessed a significant drop in sales by 15% in May alone.
The pharmaceutical products primarily drove sales. Hemlibra sales were increased by 80%, and Ocrevus sales increased by 19% in the US. A 52% increase in sales were reported for Tecentriq.
PFIZER REPORTS 10% REDUCTION IN SALES IN H1 2020
Pfizer has reported an increase in the sales of biopharma in the second quarter by 6%. The sales were primarily driven by Eliquis growth globally, Ibrance growth in the US by 11%, Prevanar 13 growth internationally by 18%, Xtandi growth was increased by 32% in the US. However, the company sales were impacted by the biosimilar competition for Enbrel, a decrease in the sales of Chantix, and 10%reduction in the sales of Ibrance in developed Europe.
NOVARTIS GUIDANCE CONFIRMED HIGHER END OPERATING INCOME AND LOWER END FOR SALES
Novartis reported a drop in sales by 4% in Q2 of 2020. The company has reported a core operating income of USD 3.7 billion, mainly due to an increase in operating income. The company reported that the drop in sales is primarily because of the drop in the ophthalmology and dermatology department. The company further stated that the sales of Sandoz declined because of low retail demand.
Also read: FDA approved Novartis’ Tabrecta for NSCLC with METex14